Martin Nicklasson new CEO and President of Biovitrum
The Board of Biovitrum has appointed Martin Nicklasson as the new CEO and President.
Martin Nicklasson, 52, is currently the CEO of AstraZeneca AB. He is also a member of the executive management of AstraZeneca Plc., where as Executive Vice President, he is head of Global Marketing.
Martin Nicklasson has previously held a number of leadership positions within AstraZeneca, Kabi Pharmacia and Astra. He has a degree in Pharmacy, and a Ph.D. in Pharmaceutical Science. Since 1985 he has been an associate professor at the Faculty of Pharmacy at Uppsala University.
“Martin Nicklasson is a skilled and experienced executive, and with his background he will be a great asset for Biovitrum. We will continue to focus on strengthening Biovitrum’s position as a leading European biopharma company, and Martin has the requisite experience for leading the development of our broad and balanced product portfolio, and further strengthening Biovitrum’s commercial position. I would also like to express my appreciation for Mats Pettersson, our CEO who is now moving on. Under his leadership, Biovitrum has made a fantastic journey, and the course Mats has set has been critical for getting Biovitrum to the advantageous position it has today,” says Biovitrum’s Chairman Håkan Åström.
“After my six years as a CEO, it feels good to be able to step back at a point when the company is standing strong, with excellent prospects for the future. It has been a fantastic time, and I believe that Biovitrum’s strong development will continue under Martin Nicklasson’s leadership,” says Biovitrum’s parting CEO Mats Pettersson.
“As the new CEO, I am very eager to get started with the plans to further develop Biovitrum as a new Swedish biopharma company. Today the company has a solid position with many opportunities to be even stronger in the future. I have followed Biovitrum for a number of years, and my impression is that the company has a rich potential. Biovitrum has also conducted a successful public listing, and I see it as a key objective to further develop the company and its personnel and thus create value for the company’s shareholders,” says Martin Nicklasson, Biovitrum’s next CEO.
Mats Pettersson will remain as CEO until Martin Nicklasson assumes his position on May 14.
For more information, please contact:
Biovitrum AB (publ)
Håkan Åström, Chairman of the Board
Cell phone: +46 70 374 72 13
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.